A Randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder

Clinical Neuropharmacology

Volumn 34, Issue 6, 2011, Pages 224-233

  Bobo, William V ^a   Epstein, Richard A ^a   Lynch, Alan ^b   Patton, Tynya D ^a   Bossaller, Nicholas A ^a   Shelton, Richard C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mental Health Cooperative Inc   (United States)

Author keywords

atypical antipsychotics; bipolar disorder; mood relapse; risperidone long acting injectable

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR MANIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EMERGENCY WARD; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; GALACTORRHEA; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE; MALE; MENSTRUATION; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RAPID CYCLING BIPOLAR DISORDER; RELAPSE; RESPITE CARE; SEDATION; SIDE EFFECT; SUICIDE ATTEMPT; WEIGHT GAIN;

ADULT; BIPOLAR DISORDER; COMMUNITY HEALTH SERVICES; DELAYED-ACTION PREPARATIONS; EMERGENCY MEDICAL SERVICES; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INJECTIONS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECURRENCE; REFERRAL AND CONSULTATION; RISPERIDONE; TREATMENT OUTCOME;

EID: 82055200176     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318237709a     Document Type: Article

References (49)

1. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537. (Pubitemid 34602935)
2. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 2004;20:139-154. (Pubitemid 38197314)
3. Dutta R, Boydell J, Kennedy N, et al. Suicide and other causes of mortality in bipolar disorder: a longitudinal study. Psychol Med 2007;37:839-847. (Pubitemid 46746328)
4. Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(suppl):1-50. (Pubitemid 34274969)
5. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-886. (Pubitemid 41032829)
6. Vieta E, Gunther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029-1049.
7. Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-35. (Pubitemid 28037545)
8. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002;63:384-390. (Pubitemid 34507214)
9. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002;159:1927-1929. (Pubitemid 35283261)
10. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164-172. (Pubitemid 34280688)
11. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153: 993-1000. (Pubitemid 26264698)
12. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-811. (Pubitemid 32577440)
13. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand 1981;64:226-237. (Pubitemid 11026617)
14. Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148:723-725. (Pubitemid 16056798)
15. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8:119-122. (Pubitemid 23188706)
16. Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006;67:107-113. (Pubitemid 43213290)
17. Keck PE Jr, McElroy SL, Strakowski SM, et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000;61(suppl 4):33-38. (Pubitemid 30158601)
18. Package insert. Risperdal Consta (risperidone) long-acting injection: US prescribing information. 2010. Titusville, NJ, Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Ref Type: Generic.
19. Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010;68(2):156-162.
20. Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009;11:827-839.
21. Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Suppl 2007;50-56. (Pubitemid 47231068)
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33. (Pubitemid 29001829)
23. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435. (Pubitemid 9006756)
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
25. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry 1987;44:540-548. (Pubitemid 17082095)
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389. (Pubitemid 9136500)
27. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-583. (Pubitemid 37289444)
28. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326. (Pubitemid 23311543)
29. Lane RD, Glazer WM, Hansen TE, et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985;173:353-357. (Pubitemid 15079180)
30. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676. (Pubitemid 19154942)
31. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
32. Muzina DJ. Pharmacologic treatment of rapid cycling and mixed states in bipolar disorder: an argument for the use of lithium. Bipolar Disord 2009;11(suppl 2):84-91.
33. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004;161:2222-2229. (Pubitemid 39587287)
34. Henry C, Van den BD, Bellivier F, et al. Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry 2003;64:331-335. (Pubitemid 36457332)
35. Young LT, Cooke RG, Robb JC, et al. Anxious and non-anxious bipolar disorder. J Affect Disord 1993;29:49-52. (Pubitemid 23272988)
36. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:807-816. (Pubitemid 39031120)
37. Coryell W, Solomon DA, Fiedorowicz JG, et al. Anxiety and outcome in bipolar disorder. Am J Psychiatry 2009;166:1238-1243.
38. Kauer-SantaposAnna M, Frey BN, Andreazza AC, et al. Anxiety comorbidity and quality of life in bipolar disorder patients. Can J Psychiatry 2007;52:175-181.
39. Salloum IM, Thase ME. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2000;2:269-280.
40. Marangell LB, Bauer MS, Dennehy EB, et al. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord 2006;8:566-575. (Pubitemid 44567139)
41. Sajatovic M, Ignacio RV, West JA, et al. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. Compr Psychiatry 2009;50:100-107.
42. Brooks JO III, Goldberg JF, Ketter TA, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry 2011;72:240-247.
43. Calabrese JR, Vieta E, El-Mallakh R, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004;56:957-963. (Pubitemid 39643054)
44. Shapiro DR, Quitkin FM, Fleiss JL. Response to maintenance therapy in bipolar illness. Effect of index episode. Arch Gen Psychiatry 1989;46:401-405. (Pubitemid 19121310)
45. Tohen M, Sutton VK, Calabrese JR, et al. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 2008.
46. Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010;13:5-14.
47. Heres S, Hamann J, Kissling W, et al. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006;67:1948-1953. (Pubitemid 46048193)
48. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 2010;175:58-62.
49. Patel MX, Nikolaou V, David AS. Psychiatristsapos attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003;33:83-89. (Pubitemid 36113403)